Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version 2.1

被引:64
|
作者
Cole, J. C. [1 ]
Lin, P. [1 ]
Rupnow, M. F. T. [2 ]
机构
[1] QualityMetric, Lincoln, RI 02865 USA
[2] Ortho McNeil Janssen Sci Affairs LLC, Titusville, NJ USA
关键词
MSQ; migraine; prophylaxis; MID; MCID; HEALTH-STATUS MEASURES; ITEM RESPONSE THEORY; INTRAINDIVIDUAL CHANGES; RELIABILITY; IMPACT; RESPONSIVENESS; PREVENTION; TOPIRAMATE; VALIDITY; SCORE;
D O I
10.1111/j.1468-2982.2009.01852.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
To propose minimal important differences (MID) for the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v2.1). To our knowledge (to date), no published MID values exist for the MSQ v2.1 in any population. Analyses were performed on data from two pivotal clinical trials of topiramate for migraine prevention (n = 916), as well as from the QualityMetric National Headache Survey (n = 1016). Analyses included both distribution- and anchor-based MID techniques as well as group- and individual-level MID values. Group-level anchor-based MID values ranged from 3.2 [Role Restrictive domain (RR)] to 7.5 [Emotional Functioning domain (EF)], setting the minimum level of appropriate MID (which can also aid with power analysis). Individual-level distribution-based MID values resulted in highly similar estimates from two large databases: median MID of 8.5 for RR, 9.2 for Role Preventive (RP) and 12.0 for EF. Finally, individual-level anchor-based MID values ranged from 5.0 (RR and RP domains) to 10.6 (EF). For group-level purposes of calculating power for future studies, an MID of 3.2, 4.6 and 7.5 for RR, RP and EF is recommended. For within-group analyses for analysing clinical trial efficacy of each patient's change with responder analyses, 5 points is necessary for RR. For RP and EF, ranges are recommended: 5.0 to 7.9 for RP and 8.0 to 10.6 for EF. These latter two domains tend to have more error in the MID, and thus a sensitivity analysis with both ends of the range should be used to confirm significant differences in responder analyses.
引用
收藏
页码:1180 / 1187
页数:8
相关论文
共 50 条
  • [1] Validity and reliability of the Migraine-Specific Quality of Life Questionnaire (MSQ version 2.1)
    Martin, BC
    Pathak, DS
    Sharfman, MI
    Adelman, JU
    Taylor, F
    Kwong, WJ
    Jhingran, P
    HEADACHE, 2000, 40 (03): : 204 - 215
  • [2] The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients
    Regina Rendas-Baum
    Lisa M. Bloudek
    Gregory A. Maglinte
    Sepideh F. Varon
    Quality of Life Research, 2013, 22 : 1123 - 1133
  • [3] The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients
    Rendas-Baum, Regina
    Bloudek, Lisa M.
    Maglinte, Gregory A.
    Varon, Sepideh F.
    QUALITY OF LIFE RESEARCH, 2013, 22 (05) : 1123 - 1133
  • [4] VALIDATING USE OF THE MIGRAINE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE VERSION 2.1 (MSQ) ACROSS MIGRAINE DISORDERS
    Elson, C. L.
    Maglinte, G. A.
    Rendas-Baum, R.
    DeRosa, M.
    Yang, M.
    Varon, S. F.
    VALUE IN HEALTH, 2010, 13 (03) : A142 - A142
  • [5] The Psychometric Properties of the Persian Migraine-Specific Quality of Life Questionnaire Version 2.1 (MSQ) in Episodic and Chronic Migraine
    Zandifar, A.
    Zandifar, S.
    Masjedi, S. S.
    Haghdoost, F.
    Asgari, F.
    Manouchehri, N.
    Banihashemi, M.
    Saadatnia, M.
    Zandifar, E.
    CEPHALALGIA, 2013, 33 (S8) : 141 - 142
  • [6] Validity and reliability of the Greek Migraine-Specific Quality of Life Questionnaire (MSQ Version 2.1-GR)
    Giannouli, Ermioni
    Giannouli, Eleni
    Alexoudi, Athanasia
    Arvaniti, Chryssa
    Fakas, Nikolaos
    Constantinidis, Theodoros S.
    Kouremenos, Evangelos
    Mitsikostas, Dimos-Dimitrios
    JOURNAL OF PATIENT-REPORTED OUTCOMES, 2024, 8 (01)
  • [7] Validation of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment
    Cole, Jason C.
    Lin, Peggy
    Rupnow, Marcia F. T.
    QUALITY OF LIFE RESEARCH, 2007, 16 (07) : 1231 - 1237
  • [8] Validation of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment
    Jason C. Cole
    Peggy Lin
    Marcia F. T. Rupnow
    Quality of Life Research, 2007, 16 : 1231 - 1237
  • [9] Assessment of reliability of the MSQ, the Migraine-Specific Quality of Life Questionnaire (Version 2.0)
    Martin, BC
    Sharfman, M
    Pathak, D
    Kwong, J
    ANNALS OF NEUROLOGY, 1998, 44 (03) : 513 - 514
  • [10] Further evaluation of the adolescent version of the migraine-specific quality of life questionnaire (MSQ-A)
    Cottrell, C.
    Holroyd, K.
    Bair, L.
    Runken, M. C.
    HEADACHE, 2008, 48 : S27 - S27